Research statistics

Cotadutide research: publications and trials

What has been published on Cotadutide: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Cotadutide works or is safe. For what it is and what the studies found, see the Cotadutide profile.

Automated weekly refresh · data through November 1, 2026

At a glance

Publications, all years

Since 2016

Publications in 2026 so far

Through November 1, 2026

Human clinical research

28.6%

14 of 49 classified

Registered clinical trials

ClinicalTrials.gov

Randomized controlled trials

Publications reporting an RCT in people

Systematic reviews and meta-analyses

Preclinical studies

36.7%

11 animal · 2 in vitro · 5 computational

Records that only mention it

Not counted above

Status in the library: In clinical trials. Groups: GLP-1 receptor agonists.

What to keep in mind

Some completed trials have neither posted results nor a linked results publication.

Publications by year

Cotadutide publications by year and evidence

Counted PubMed publications by year of first publication. * 2026 runs to November 1, 2026. A larger bar is more publications, not stronger evidence.

Show the data

Year	Human clinical research	Preclinical (animal, in vitro, computational)	Reviews and meta-analyses	Other and not yet classified	Total
2016	0	1	0	0	1
2018	2	0	0	1	3
2020	1	3	0	0	4
2021	2	0	0	0	2
2022	1	1	2	1	5
2023	3	6	0	0	9
2024	4	3	2	0	9
2025	1	3	5	0	9
2026 (to date)	0	1	6	0	7

Study types

Randomized controlled trial	12
Animal study	11
Review	8
Computational study	5
Systematic review	4
Meta-analysis	3
Other clinical trial	2
In vitro study	2
Correction or retraction notice	1
Editorial, letter or other	1

Research areas

From MeSH major topics. A paper can be in several areas.

Metabolic health	42
Endocrinology	30
Obesity and weight management	16
Gastrointestinal	12
Reproductive and sexual health	7
Cardiovascular	2
Oncology	1

Registered clinical trials

9 of 22 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 22 · Terminated: 2
Phase 1: 12 · Phase 1 / Phase 2: 1 · Phase 2: 11

Trial	Status	Phase	Started	Results
A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy ParticipantsNCT05668936 · 31 enrolled	Terminated	Phase 1	2023-01	—
Pharmacokinetics of Cotadutide in Participants With Hepatic ImpairmentNCT05517226 · 24 enrolled	Terminated	Phase 1	2022-09	—
A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With FibrosisNCT05364931 · 54 enrolled	Completed	Phase 2	2022-07	Posted
A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy SubjectsNCT05294458 · 10 enrolled	Completed	Phase 1	2022-03	—
Chinese Multiple Dose Escalation (MDE) High Dose StudyNCT05437848 · 16 enrolled	Completed	Phase 1	2022-02	—
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes MellitusNCT04515849 · 248 enrolled	Completed	Phase 2	2020-08	Posted
Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes MelitusNCT04208620 · 16 enrolled	Completed	Phase 1	2020-01	—
A Study Investigating the Pharmacokinetics of a Single Dose Administration of CotadutideNCT04091373 · 36 enrolled	Completed	Phase 1	2019-09	—
A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.NCT04019561 · 74 enrolled	Completed	Phase 2	2019-09	Posted
A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes MellitusNCT03745937 · 20 enrolled	Completed	Phase 2	2019-01	Posted
A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes MellitusNCT03596177 · 28 enrolled	Completed	Phase 2	2018-09	Posted
A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese ParticipantsNCT03625778 · 51 enrolled	Completed	Phase 1	2018-08	—
Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 DiabetesNCT03645421 · 61 enrolled	Completed	Phase 2	2018-08	Posted
A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well ToleratedNCT03550378 · 41 enrolled	Completed	Phase 2	2018-06	Posted
A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.NCT03555994 · 51 enrolled	Completed	Phase 2	2018-05	Posted
Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 DiabetesNCT03444584 · 49 enrolled	Completed	Phase 2	2018-05	Posted
A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese DescentNCT03385369 · 32 enrolled	Completed	Phase 1	2018-01	—
A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382NCT03341013 · 24 enrolled	Completed	Phase 1	2017-11	—
Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382NCT03347968 · 22 enrolled	Completed	Phase 1	2017-11	—
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment SubjectsNCT03235375 · 37 enrolled	Completed	Phase 1	2017-10	—
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.NCT03244800 · 65 enrolled	Completed	Phase 2	2017-09	Posted
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 DiabetesNCT03235050 · 834 enrolled	Completed	Phase 2	2017-08	Posted
A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes MellitusNCT02548585 · 113 enrolled	Completed	Phase 1, Phase 2	2015-12	Posted
A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy VolunteersNCT02394314 · 362 enrolled	Completed	Phase 1	2015-02	—

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.
Obesity (Silver Spring, Md.) · November 4, 2025 · Meta-analysis · cited 2 times · open access
PMID 41189318 · DOI 10.1002/oby.70054 · Reviews and meta-analyses
Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials.
Endocrine · May 13, 2024 · Meta-analysis · cited 14 times
PMID 38740695 · DOI 10.1007/s12020-024-03857-6 · Reviews and meta-analyses
Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
BMC endocrine disorders · April 29, 2022 · Meta-analysis · cited 23 times · open access
PMID 35488292 · DOI 10.1186/s12902-022-01031-5 · Reviews and meta-analyses
Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
Diabetes, obesity & metabolism · September 29, 2026 · Systematic review · cited 0 times · open access
PMID 42811393 · DOI 10.1111/dom.71400 · Reviews and meta-analyses
Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.
Endocrinology, diabetes & metabolism · January 1, 2026 · Systematic review · cited 2 times · open access
PMID 41466530 · DOI 10.1002/edm2.70157 · Reviews and meta-analyses
Glycemic control, weight-loss effects, and safety of cotadutide in individuals with type 2 diabetes: A systematic review and meta-analysis.
World journal of diabetes · December 1, 2025 · Systematic review · cited 3 times · open access
PMID 41480597 · DOI 10.4239/wjd.v16.i12.112830 · Reviews and meta-analyses
Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis.
Acta diabetologica · June 5, 2025 · Systematic review · cited 12 times · open access
PMID 40471293 · DOI 10.1007/s00592-025-02534-y · Reviews and meta-analyses
Pharmacokinetic-pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus.
British journal of clinical pharmacology · May 9, 2025 · Randomized controlled trial · cited 2 times · open access
PMID 40344607 · DOI 10.1002/bcp.70093 · Human clinical research
A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.
Kidney international · August 31, 2024 · Randomized controlled trial · cited 48 times · open access
PMID 39218393 · DOI 10.1016/j.kint.2024.08.023 · Human clinical research
Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · May 9, 2024 · Randomized controlled trial · cited 57 times · open access
PMID 38729399 · DOI 10.1016/j.cgh.2024.04.017 · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.
Diabetes care · May 20, 2021 · Randomized controlled trial · cited 322 times · open access
PMID 34016612 · DOI 10.2337/dc20-2151 · Human clinical research
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Lancet (London, England) · June 23, 2018 · Randomized controlled trial · cited 297 times
PMID 29945727 · DOI 10.1016/s0140-6736(18)30726-8 · Human clinical research
Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.
Nature metabolism · May 21, 2020 · Animal study · cited 266 times · open access
PMID 32478287 · DOI 10.1038/s42255-020-0209-6 · Animal studies
Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
Diabetes, obesity & metabolism · August 15, 2016 · Animal study · cited 238 times · open access
PMID 27377054 · DOI 10.1111/dom.12735 · Animal studies
Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist.
The Journal of clinical endocrinology and metabolism · March 1, 2020 · Randomized controlled trial · cited 121 times · open access
PMID 31608926 · DOI 10.1210/clinem/dgz047 · Human clinical research

Latest publications

From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease.
Frontiers in pharmacology · October 13, 2026 · Review · cited 0 times · open access
PMID 42947668 · DOI 10.3389/fphar.2026.1784959 · Reviews and meta-analyses
Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
Diabetes, obesity & metabolism · September 29, 2026 · Systematic review · cited 0 times · open access
PMID 42811393 · DOI 10.1111/dom.71400 · Reviews and meta-analyses
Single or multiple nutritional hormone receptor modulators for chronic kidney disease.
Clinical kidney journal · September 7, 2026 · Review · cited 0 times · open access
PMID 42959190 · DOI 10.1093/ckj/sfag311 · Reviews and meta-analyses
Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.
Cureus · June 29, 2026 · Review · cited 0 times · open access
PMID 42529769 · DOI 10.7759/cureus.111728 · Reviews and meta-analyses
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
Endocrinology, diabetes & metabolism · March 1, 2026 · Review · cited 2 times · open access
PMID 41787737 · DOI 10.1002/edm2.70187 · Reviews and meta-analyses
Systemic Pharmacokinetic Principles of Therapeutic Peptides.
Clinical pharmacokinetics · February 9, 2026 · Computational study · cited 3 times · open access
PMID 41661442 · DOI 10.1007/s40262-025-01615-z · Computational studies
Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.
Endocrinology, diabetes & metabolism · January 1, 2026 · Systematic review · cited 2 times · open access
PMID 41466530 · DOI 10.1002/edm2.70157 · Reviews and meta-analyses
Glycemic control, weight-loss effects, and safety of cotadutide in individuals with type 2 diabetes: A systematic review and meta-analysis.
World journal of diabetes · December 1, 2025 · Systematic review · cited 3 times · open access
PMID 41480597 · DOI 10.4239/wjd.v16.i12.112830 · Reviews and meta-analyses
Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.
Obesity (Silver Spring, Md.) · November 4, 2025 · Meta-analysis · cited 2 times · open access
PMID 41189318 · DOI 10.1002/oby.70054 · Reviews and meta-analyses
Efficacy of Dual Glucagon and Glucagon-like Peptide-1 Receptor Agonists Across the Cardiometabolic Continuum: A Review of Current Clinical Evidence.
Reviews in cardiovascular medicine · July 28, 2025 · Review · cited 9 times · open access
PMID 40776973 · DOI 10.31083/rcm39691 · Reviews and meta-analyses

Browse all 49 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Cotadutide; MEDI0382

((TITLE_ABS:"Cotadutide" OR CHEM:"Cotadutide") OR (TITLE_ABS:"MEDI0382" OR CHEM:"MEDI0382" OR TITLE_ABS:"MEDI 0382" OR CHEM:"MEDI 0382")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 2). Cotadutide research statistics (Version weekly-2026-11-01) [Statistic]. Peptide Library. https://bestpeptidecalculator.app/research/peptides/cotadutide